Profile data is unavailable for this security.
About the company
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
- Revenue in INR (TTM)31.51bn
- Net income in INR220.00m
- Incorporated1999
- Employees2.30k
- LocationWockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
- Phone+91 2 226534444
- Fax+91 2 226523905
- Websitehttps://www.wockhardt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concord Biotech Ltd | 11.59bn | 3.12bn | 123.91bn | 1.57k | 39.86 | -- | 32.55 | 10.69 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 131.59bn | 990.00 | 21.51 | -- | 18.98 | 6.30 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Granules India Ltd | 50.92bn | 5.45bn | 136.46bn | 4.07k | 25.02 | -- | 16.57 | 2.68 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 144.59bn | 978.00 | 33.53 | -- | 17.04 | 1.83 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 147.56bn | 4.20k | 9.48 | -- | 8.20 | 3.24 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 151.33bn | 16.57k | 24.01 | -- | 16.36 | 2.08 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 167.51bn | 1.80k | 93.51 | -- | 63.77 | 10.63 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 193.61bn | 3.40k | 59.13 | -- | 39.35 | 8.92 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 195.93bn | 3.56k | 44.74 | -- | 25.84 | 6.37 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 219.61bn | 7.13k | -- | -- | 31.74 | 2.48 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 222.98bn | 802.00 | 110.96 | -- | 92.31 | 10.24 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Wockhardt Ltd | 31.51bn | 220.00m | 226.64bn | 2.30k | 1,054.18 | -- | 96.44 | 7.19 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Pfizer Ltd | 24.82bn | 8.54bn | 230.45bn | 1.60k | 27.00 | -- | 25.24 | 9.28 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 282.22bn | 6.73k | 32.43 | -- | 21.70 | 3.19 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Gland Pharma Ltd | 61.13bn | 8.47bn | 293.40bn | 4.35k | 34.63 | -- | 23.32 | 4.80 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 41.93bn | 7.54bn | 303.69bn | 5.52k | 39.88 | -- | 32.56 | 7.24 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
Data as of Feb 13 2026. Currency figures normalised to Wockhardt Ltd's reporting currency: Indian Rupee INR
10.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 3.34m | 2.05% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 3.21m | 1.97% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Dec 2025 | 2.26m | 1.39% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jan 2026 | 1.35m | 0.83% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 1.18m | 0.72% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.09m | 0.67% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 1.07m | 0.66% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Jan 2026 | 1.04m | 0.64% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 986.19k | 0.61% |
| ITI Asset Management Ltd. (India)as of 31 Jan 2026 | 964.78k | 0.59% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
